A rapid and selective HPLC-UV method for the quantitation of efavirenz in plasma from patients on concurrent HIV/AIDS and tuberculosis treatments

Biomedical Chromatography

Volumn 27, Issue 11, 2013, Pages 1554-1559

  Bienvenu, Emile ^a   Hoffmann, Kurt Jürgen ^a   Ashton, Michael ^a   Kayumba, Pierre Claver ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b RWANDA BIOMEDICAL CENTER   (Rwanda)

Author keywords

Efavirenz; HPLC; Plasma; Quantitation

Indexed keywords

DISEASES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TUBES (COMPONENTS);

ANALYSIS TIME; CHROMATOGRAPHIC SEPARATIONS; EFAVIRENZ; HIV/AIDS; HPLC; HPLC-UV; INTERNAL STANDARDS; MOBILE PHASIS; PLASMA PROTEIN; QUANTITATION;

CLINICAL RESEARCH;

ABACAVIR; ACETONITRILE; EFAVIRENZ; ETHAMBUTOL; FORMIC ACID; ISONIAZID; LAMIVUDINE; NEVIRAPINE; PLASMA PROTEIN; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN; RITONAVIR; STAVUDINE; STREPTOMYCIN; SULFAMETHOXAZOLE; TENOFOVIR; TRIMETHOPRIM; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ACCURACY; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS PATIENT; ARTICLE; CENTRIFUGATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIXED INFECTION; PRECIPITATION; QUANTITATIVE ANALYSIS; TUBERCULOSIS;

EFAVIRENZ; HPLC; PLASMA; QUANTITATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; BENZOXAZINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; HUMANS; LIMIT OF DETECTION; MALE; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TUBERCULOSIS;

EID: 84885896966     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2959     Document Type: Article

References (16)

1. Dimeski G. Interference testing. Clinical Biochemist Reviews 2008; 29: 43-48.
2. Fox D, O'Connor R, Mallon P and McMahon G. Simultaneous determination of efavirenz, rifampicin and its metabolite desacetyl rifampicin levels in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2011; 56: 785-791.
3. Gallicano K. Antiretroviral-drug concentrations in semen. Antimicrobial Agents and Chemotherapy 2000; 44: 1117-1118.
4. King J and Aberg JA. Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS 2008; 22: 1709-1717.
5. Kwara A, Tashima KT, Dumond JB, Poethke P, Kurpewski J, Kashuba AD, Court MH and Greenblatt DJ. Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers. Antimicrobial Agents and Chemotherapy 2011; 55: 3527-3533.
6. Mogatle S and Kanfer I. Rapid method for the quantitative determination of efavirenz in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2009; 49: 1308-1312.
7. Mutlib AE, Chen H, Nemeth GA, Markwalder JA, Seitz SP, Gan LS and Christ DD. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metabolism and Disposition 1999; 27: 1319-1333.
8. Ogburn ET, Jones DR, Masters AR, Xu C, Guo Y and Desta Z. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metabolism and Disposition 2010; 38: 1218-1229.
9. Önal A. Analysis of antiretroviral drugs in biological matrices for therapeutic drug monitoring. Journal of Food and Drug Analysis 2006; 14: 99-119.
10. Pozniak AL, Coyne KM, Miller RF, Lipman MC, Freedman AR, Ormerod LP, Johnson MA, Collins S. and Lucas SB; British HIV Association Guidelines Subcommittee. British HIV Association guidelines for the treatment of TB/HIV coinfection 2011. HIV Medicine 2011; 12: 517-524.
11. Ramachandran G, Kumar AK, Swaminathan S, Venkatesan P, Kumaraswami V and Greenblatt DJ. Simple and rapid liquid chromatography method for determination of efavirenz in plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2006; 835: 131-135.
12. Sánchez A, Cabrera S, Santos D, Valverde MP, Fuertes A, Domínguez-Gil A and García MJ; Tormes Group. Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients. Antimicrobial Agents and Chemotherapy 2011; 55: 5314-5324.
13. Saras-Nacenta M, López-Púa Y, Lípez-Cortés LF, Mallolas J, Gatell JM and Carné X. Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography. B, Biomedical Sciences and Applications 2001; 763: 53-59.
14. USFDA. Guidance for Industry, Bioanalytical Method Validaton. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine, 2001.
15. Veldkamp AI, van Heeswijk RP, Meenhorst PL, Mulder JW, Lange JM, Beijnen JH and Hoetelmans RM. Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography. B, Biomedical Sciences and Applications 1999; 734: 55-61.
16. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA and Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. Journal of Pharmacology and Experimental Therapeutics 2003; 306: 287-300.